Successful switch from inhalative iloprost to oral bosentan in portopulmonary hypertension associated with liver cirrhosis

Wiener Klinische Wochenschrift

Volumn 116, Issue 17-18, 2004, Pages 627-630

  Molnar, Clemens ^a   Alber, Hannes ^a   Colleselli, Daniela ^a   Vogel, Wolfgang ^a   Kähler, Christian M ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Bosentan; Cirrhosis; Iloprost; Liver cirrhosis; Liver transplantation; Pulmonary hypertension

Indexed keywords

BOSENTAN; CALCIUM ANTAGONIST; ENDOTHELIN RECEPTOR ANTAGONIST; ILOPROST; NIFEDIPINE; PROSTACYCLIN; PROSTACYCLIN DERIVATIVE; PROSTANOID;

ADULT; ARTICLE; CASE REPORT; DISEASE ASSOCIATION; ESOPHAGUS VARICES BLEEDING; FEMALE; HUMAN; LIVER CIRRHOSIS; LIVER TOXICITY; LIVER TRANSPLANTATION; NEPHROTOXICITY; PULMONARY HYPERTENSION; THROMBOCYTE AGGREGATION;

ADMINISTRATION, INHALATION; ADMINISTRATION, ORAL; ANTIHYPERTENSIVE AGENTS; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HEMODYNAMIC PROCESSES; HUMANS; HYPERTENSION, PORTAL; HYPERTENSION, PULMONARY; ILOPROST; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; SULFONAMIDES; TIME FACTORS;

EID: 5344233369     PISSN: 00435325     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00508-004-0238-2     Document Type: Article

References (17)

1. Naeije R (2003) Hepatopulmonary syndrome and portopulmonary hypertension. Swiss Med Wkly 133: 163-169
2. Plotkin JS, Kuo PC, Rubin LJ, Gaine S, Howell CD, Laurin J, et al (1998) Successful use of chronic epoprostenol as a bridge to liver transplantation in severe portopulmonary hypertension. Transplantation 65: 457-459
3. Budhiraja R, Hassoun PM (2003) Portopulmonary hypertension: a tale of two circulations. Chest 123: 562-576
4. Rafanan AL, Maurer J, Mehta AC, Schilz R (2000) Progressive portopulmonary hypertension after liver transplantation treated with epoprostenol. Chest 118: 1497-1500
5. Kahler CM, Graziadei I, Wiedermann CJ, Kneussl M, Vogel W (2000) Successful use of continuous intravenous prostacyclin in a patient with severe portopulmonary hypertension. Wien Klin Wochenschr 112: 637-640
6. Krowka MJ, Frantz RP, McGoon MD, Severson C, Plevak DJ, Wiesner RH (1999) Improvement in pulmonary hemo dynamics during intravenous epoprostenol (prostacyclin): a study of 15 patients with moderate to severe portopulmonary hypertension. Hepatology 30: 641-648
7. Kuo PC, Johnson LB, Plotkin JS, Howell CD, Bartlett ST, Rubin LJ (1997) Continuous intravenous infusion of epoprostenol for the treatment of portopulmonary hypertension. Transplantation 63: 604-606
8. Schroeder RA, Rafii AA, Plotkin JS, Johnson LB, Rustgi VA, Kuo PC (2000) Use of aerosolized inhaled epoprostenol in the treatment of portopulmonary hypertension. Transplantation 70: 548-550
9. Kuo PC, Plotkin JS, Gaine S, Schroeder RA, Rustgi VA, Rubin LJ, Johnson LB (1999) Portopulmonary hypertension and the liver transplant candidate. Transplantation 67: 1087-1093
10. Hadengue A, Benhayoun MK, Lebrec D, Benhamou JP (1991) Pulmonary hypertension complicating portal hypertension: prevalence and relation to splanchnic hemodynamics. Gastroenterology 100: 520-528
11. Mandell MS, Groves BM (1996) Pulmonary hypertension in chronic liver disease. Clin Chest Med 17: 17-33
12. Robalino BD, Moodie DS (1991) Association between primary pulmonary hypertension and portal hypertension: analysis of its pathophysiology and clinical, laboratory and hemodynamic manifestations. J Am Coll Cardiol 17: 492-498
13. Benjaminov FS, Prentice M, Sniderman KW, Siu S, Liu P, Wong F (2003) Portopulmonary hypertension in decompensated cirrhosis with refractory ascites. Gut 52: 1355-1362
14. Yokoyama Y, Toth B, Kitchens WC, Schwacha M, Bland K, Chaudry I (2003) Role of thromboxane in producing portal hypertension following trauma-hemorrhage. Am J Physiol Gastrointest Liver Physiol 285: G1293-G1299
15. Olschewski H, Simonneau G, Galie N, Higgenbottom T, Naeije J, Rubin L et al. (2002) Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 347: 322-329
16. Sitbon O, Badesch DB, Channick RN, Frost A, Robbin I, Simmoneuau G, et al (2003) Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension: a 1-year follow-up study. Chest 124: 247-254
17. Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, et al (2002) Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 346: 896-903